Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $4.37 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• FirstCash to acquire UK pawn operator Ramsdens for £206 million